Replies to post #263698 on Innovation Pharmaceuticals Inc (IPIX)

[DaubersUP]

Thanks for clarification on GI and Mucositis.

[farrell90]

The Brilacidin for Ulcerative Proctitis study was for more extensive disease than just the anus which is just the tissue of the distal GI system and is short.

The B for UP included the rectum and the sigmoid colon which is much longer. The endoscopy photos published were of the distal colon.

http://www.ipharminc.com/press-release/2017/1/22/cellceutixs-brilacidin-demonstrates-promise-in-treating-ulcerative-colitis-supported-by-endoscopic-assessment-patient-reported-outcomes

The protocol included distal disease which extended 40 cm {about 16 inches} from the internal anal opening which would be roughly 1/4 of the colon.

http://www.ipharminc.com/press-release/2016/11/10/cellceutix-receives-update-on-first-patient-enrollment-in-phase-2-proof-of-concept-study-of-brilacidin-for-ulcerative-proctitis

http://www.ipharminc.com/brilacidin-1

Good luck,Farrell

[TheDane]

Got it. But I’m missing the overall point of the discussion. Is the assumption that the first Term Sheet signer is no longer in play (nor any others) because now another BIG PHARMA! has “first right of negotiation?”